Pieris Pharmaceuticals.jpg
Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 09, 2018 07:00 ET | Pieris Pharmaceuticals, Inc.
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ONTHURSDAY, AUGUST 9, 2018 AT 8:00 AM EDT BOSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage...
Pieris Pharmaceuticals.jpg
Pieris Pharmaceuticals to Present at the 2018 Wedbush PacGrow Healthcare Conference
August 08, 2018 08:00 ET | Pieris Pharmaceuticals, Inc.
BOSTON, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
Pieris Pharmaceuticals.jpg
Pieris Pharmaceuticals to Host Second Quarter 2018 Investor Call and Corporate Update on August 9, 2018
August 01, 2018 08:00 ET | Pieris Pharmaceuticals, Inc.
BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
Pieris Pharmaceuticals.jpg
Pieris Pharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference
May 31, 2018 08:00 ET | Pieris Pharmaceuticals, Inc.
BOSTON, May 31, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...
Pieris Pharmaceuticals.jpg
Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 10, 2018 07:00 ET | Pieris Pharmaceuticals, Inc.
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ONTHURSDAY, MAY 10, 2018 AT 8:00 AM EDT BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage...
Pieris Pharmaceuticals.jpg
Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference
May 03, 2018 08:00 ET | Pieris Pharmaceuticals, Inc.
BOSTON, May 03, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform...